Skip to main content
. Author manuscript; available in PMC: 2020 Sep 24.
Published in final edited form as: Eur J Cancer. 2020 Apr 16;131:89–97. doi: 10.1016/j.ejca.2020.02.048

Table 1.

Baseline characteristics

FIRE-3 TRIBE FIRE-3

Treatment FOLFIRI+Bev FOLFIRI+Bev FOLFIRI+Cet

N N=292 N=210 N=271 P-valuea
Sex 0.068
 Male 507 191(65%) 126(60%) 190(70%)
 Female 266 101(35%) 84(40%) 81(30%)
Age <0.001
 <65 421 144(49%) 139(66%) 138(51%)
 ≥65 352 148(51%) 71(34%) 133(49%)
ECOG performance status <0.001
 0 473 160(55%) 173(82%) 140(52%)
 1–2 299 132(45%) 36(17%) 131(48%)
 Unspecified 1 - 1(0%) -
Primary tumor site 0.13
 Right 181 75(26%) 53(25%) 53(20%)
 Left 563 210(72%) 142(68%) 211(78%)
 Unspecified 29 7(2%) 15(7%) 7(3%)
Liver limited metastases 0.87
 Yes 250 95(33%) 65(31%) 90(33%)
 No 523 197(67%) 145(69%) 181(67%)
Number of metastatic sites 0.39
 1 289 105(36%) 89(42%) 95(35%)
 2 246 83(28%) 85(40%) 78(29%)
 ≥3 145 56(19%) 36(17%) 53(20%)
 Unspecified 93 48(16%) - 45(17%)
Primary tumor resection <0.001
 Yes 615 252(86%) 132(63%) 231(85%)
 No 157 40(14%) 78(37%) 39(14%)
 Unspecified 1 - - 1(0%)
Adjuvant chemotherapy 0.062
 Yes 137 53(18%) 27(13%) 57(21%)
 No 635 239(82%) 183(87%) 213(79%)
 Unspecified 1 - - 1(0%)
KRAS status <0.001
 Wild-type 556 244(84%) 86(41%) 226(83%)
 Mutant 181 48(16%) 88(42%) 45(17%)
 Unspecified 36 - 36(17%) -
RAS status <.0001
 Wild-type 423 195(67%) 49(23%) 179(66%)
 Mutant 275 84(29%) 110(52%) 81(30%)
 Unspecified 75 13(4%) 51(24%) 11(4%)
BRAF status 0.63
 Wild-type 664 258(88%) 163(78%) 243(90%)
 Mutant 57 25(9%) 11(5%) 21(8%)
 Unspecified 52 9(3%) 36(17%) 7(3%)

The unspecified group was not included in the analysis.

a

The P-value was based on the Chi-square test.